Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2-Reference-Cited by-同舟云学术

Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2

Published:2018-05-24 Issue:11 Volume:61 Page:4946-4960
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Fehl Charlie¹,Vogt Caleb D.²,Yadav Rahul³,Li Kelin²,Scott Emily E.³⁴,Aubé Jeffrey²^ORCID

Affiliation:

1. Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66047, United States

2. Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States

3. Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States

4. Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, United States

Funder

University of Michigan

University of North Carolina

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00419

Reference41 articles.

1. American Cancer Society. Cancer Facts & Figures 2017. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html (accessed Jan 24, 2018).

2. Basis for hormonal management of advanced prostate cancer

3. Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer

4. Abiraterone and Increased Survival in Metastatic Prostate Cancer

5. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1;Toxicology and Applied Pharmacology;2024-05

2. Steroidogenic cytochrome P450 enzymes as drug target;Toxicological Research;2024-04-22

3. Cytochrome P450 enzymes as drug targets in human disease;Drug Metabolism and Disposition;2023-10-04

4. Exploring the Potential of Sulfur Moieties in Compounds Inhibiting Steroidogenesis;Biomolecules;2023-09-05

5. Allosteric modulation of cytochrome P450 enzymes by the NADPH cytochrome P450 reductase FMN-containing domain;Journal of Biological Chemistry;2023-09